Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | RXRG | P48443 | 2/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446223 | 0.85 | RXRA (0.71) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL8027909 | 0.83 | RXRA (0.53) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL447853 | 0.83 | MAPT (0.51) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL27532762 | 0.82 | CYP19A1 (0.48) | RXRARXRBRXRGSGMS2MAPT | |
| Formaldehyde SCHEMBL27873826 | 0.81 | RXRA (0.70) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL1681361 | 0.81 | RXRA (0.54) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL16797619 | 0.79 | RXRA (0.56) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL448625 | 0.79 | RXRA (0.59) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL544055 | 0.79 | TDP1 (0.44) | RXRARXRBRXRGSGMS2MAPT | |
| SCHEMBL3150218 | 0.78 | SGMS2 (0.66) | RXRARXRBRXRGSGMS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | RXRA 364/4885RXRB 333/4885RXRG 328/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | RXRA 1401/4885RXRB 1484/4885RXRG 1825/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | RXRA 792/4885RXRB 560/4885RXRG 800/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | RXRA 961/4885RXRB 831/4885RXRG 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.